GlassScriptPhysician profile
Joel V Mabalot
NPI 1881782233
$862.38
in general payments reported to CMS, 2019-2025
20 companies · $349 in 2025
The $349 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $94.09 · 2021: $80.98 · 2022: $45.73 · 2023: $41.08 · 2024: $80.54 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $470.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $141.64 | 2019-2020 | |
| Insulet Corporation | $125.00 | 2020-2025 | Omnipod |
| Amgen INC. | $93.23 | 2022-2025 | Evenity, Tepezza |
| Novo Nordisk INC | $86.62 | 2023-2025 | Rybelsus, Ozempic |
| Dexcom, INC. | $60.72 | 2021-2024 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $39.81 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.01 | 2020-2021 | |
| Radius Health, INC. | $30.25 | 2019 | |
| Ascensia Diabetes Care US INC. | $27.95 | 2025 | |
| Inspire Medical Systems, INC. | $25.68 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $24.95 | 2019 | |
| Sanofi US Services INC. | $24.11 | 2023 | |
| Mannkind Corporation | $23.55 | 2025 | |
| Xeris Pharmaceuticals, INC. | $23.42 | 2025 | Gvoke Hypopen |
| Shire North American Group INC | $18.31 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $18.09 | 2025 | Yorvipath |
| Abbott Laboratories | $16.91 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.04 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.05 | 2019 | |
| Abbvie INC. | $14.04 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Mabalot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.